Background and aims: Among subjects with high-density-lipoprotein cholesterol (HDL-C) below the 1st percentile in the general population, we identified a heterozygous variant OSBPL1A p.C39X encoding a short truncated protein fragment that co-segregated with low plasma HDL-C. Methods: We investigated the composition and function of HDL from the carriers and non-carriers and studied the properties of the mutant protein in cultured hepatocytes. Results: Plasma HDL-C and apolipoprotein (apo) A-I were lower in carriers versus non-carriers, whereas the other analyzed plasma components or HDL parameters did not differ. Sera of the carriers displayed a reduced capacity to act as cholesterol efflux acceptors (p < 0.01), whereas the cholesterol acceptor capacity of their isolated HDL was normal. Fibroblasts from a p.C39X carrier showed reduced cholesterol efflux to lipid-free apoA-I but not to mature HDL particles, suggesting a specific defect in ABCA1-mediated efflux pathway. In hepatic cells, GFP-OSBPL1A partially co-localized in endosomes containing fluorescent apoA-I, suggesting that OSBPL1A may regulate the intracellular handling of apoA-I. The GFP-OSBPL1A-39X mutant protein remained in the cytosol and failed to interact with Rab7, which normally recruits OSBPL1A to late endosomes/lysosomes, suggesting that this mutation represents a lossof-function. Conclusions: The present work represents the first characterization of a human OSBPL1A mutation. Our observations provide evidence that a familial loss-of-function mutation in OSBPL1A affects the first step of the reverse cholesterol transport process and associates with a low HDL-C phenotype. This suggests that rare mutations in OSBPL genes may contribute to dyslipidemias.
A loss-of-function variant in OSBPL1A predisposes to low plasma HDL cholesterol levels and impaired cholesterol efflux capacity 
Introduction
Plasma high-density-lipoproteins (HDL) comprise a heterogeneous population of particles which differ in density, particle size, charge, and composition. Epidemiological studies have consistently shown an inverse correlation between plasma HDL cholesterol (HDL-C) as well as apolipoprotein A-I (apoA-I) levels and cardiovascular disease (CVD) risk [1, 2] . However, recent failures of drugs that target HDL-C levels [3, 4] , together with evidence from Mendelian randomization studies indicate that HDL may not be causally related to cardiovascular disease [5, 6] . A number of common and rare genetic variations have been shown to be associated with altered plasma HDL-C concentrations. The best recognized among these are cholesteryl ester transfer protein (CETP) and endothelial lipase (LIPG) loss-of-function variants which cause markedly raised HDL-C levels, but do not protect against coronary heart disease (CHD) [6e8] . Additional genetic variants associated with elevated HDL-C levels include TRIB1, APOA1/C3/A4/A5 gene cluster, ANGPTL4 and GALNT2 [6] .
Losseofefunction mutants in APOAI, ABCA1 and LCAT cause extremely low HDL-C levels [9] . Whether these mutations cause increased CVD risk is still a matter of debate [10, 11] . On the other hand, a hypothesis on the importance of HDL functionality has emerged, suggesting the presence of distinct functional HDL subpopulations [12, 13] . In a previous study, we discovered an increased number of rare non-synonymous variants in lipid-related genes in a cohort of subjects with extreme plasma HDL-C concentrations (<1st or >99th percentile) [14] . Among the identified variants in subjects with low HDL-C (<1%) there was a nonsense mutation p.C39X in OSBPL1A, which encodes a homolog of Oxysterol-binding protein, OSBP [15, 16] .
The human OSBPL genes constitute a family with 12 members the protein products of which are characterized by a carboxyterminal OSBP-related ligand-binding domain (ORD). These proteins are suggested to act as sterol and phospholipid transporters or sensors at organelle interfaces [17, 18] . OSBPL1A targets late endocytic compartments (LE) via the small GTPase Rab7 and the endoplasmic reticulum (ER) through VAMP-associated proteins (VAPA and -B) [19, 20] . OSBPL1A regulates the interactions of LE with ER membranes in a sterol-specific manner. OSBPL1A controls the motility, subcellular distribution and tethering of the endosomes by bridging between the ER and LE and through regulation of dynein/ dynactin and homotypic fusion and protein sorting (HOPS) complexes [21e23] .
The role of OSBPL1A in lipid metabolism remains to be elucidated. Overexpression of human OSBPL1A in mouse macrophages disturbed cholesterol efflux to HDL and enhanced atherogenesis in low-density lipoprotein receptor knock-out animals [24] . On the other hand, knock-down of Osbpl1a in mouse macrophages impaired the efflux of endocytosed LDL cholesterol to extracellular apoA-I, indicating that the function of Osbpl1a in LE may involve cross-talk with ATP-binding cassette transporter A1 (Abca1)-mediated pathways of cholesterol efflux, and could thus impact the biogenesis of HDL in the liver and the intestine [22] .
In the present study, we characterize the composition and function of HDL from heterozygous carriers of an OSBPL1A p.C39X mutation. We further demonstrate an abnormal subcellular localization and a functional defect of the mutant protein, suggesting that this OSBPL1A loss of function mutation affects cholesterol removal from cells associated with the low HDL-C phenotype in the mutant carriers.
Materials and methods

Study subjects
A cohort of individuals with very high (n ¼ 40) and very low (n ¼ 40) plasma HDL-C levels (<1st and >99th percentile for age and gender) from the general population was studied to identify the genetic background underlying the HDL-C phenotype as described [14] . Coding sequence and exon-intron boundaries of 195 lipid-related genes and 78 lipid-unrelated genes were sequenced using Agilent Sureselect custom capture library on the Illumina HiSeq 2000 platform. In 1 individual with low HDL a nonsense mutation in OSBPL1A (NM_080597.2) was identified and further family expansion was done to evaluate co-segregation of each mutation with the low HDL-C phenotype. Genomic DNA was extracted from 10 ml whole blood on an AutopureLS system (Gentra Systems, Minneapolis, MN) according to the manufacturer's protocol. The primers to amplify the coding and intron-exon boundaries were designed using Primer 3 software (exon 1 p.C39X; c.112-115dup: forward 5 0 -TCC AAT CTG TGG GGT TCT TC-3 0 , reverse 5 0 -CCC CTT TCT GTA TTA GCA GGT G-3 0 and sequenced as described elsewhere [25] .
Written informed consent was obtained from all individuals and the study was approved by the Medical Ethical Committee of the Amsterdam Medical Center.
Analytical procedures
Blood was obtained after overnight fasting in EDTA-containing tubes and directly placed on ice. Plasma was isolated by centrifugation at 4 C, 1700 Â g for 15 min and stored at À80 C for further analysis. Plasma and HDL phospholipids were analyzed using the Phospholipids B kit (Wako Chemicals, Osaka, Japan) or Pureauto S PL-kit (Daiichi Pure Chemicals, Tokyo, Japan); triglycerides using the Triglycerides GPO-PAP-kit (Roche Diagnostics, Mannheim, Germany); free cholesterol using the Wako Free Cholesterol C kit (Wako Chemicals) and total cholesterol using the Cholesterol CHOD-PAP kit (Roche Diagnostics). Human apolipoprotein E (apoE) was detected by ELISA as described previously with some modifications [26] . Quantitation of human apoA-I was performed with a sandwich ELISA. Briefly, the wells were coated with a polyclonal rabbit antibody against human apoA-I. The bound apoA-I protein was detected with a HRP-conjugated rabbit anti-human apoA-I immunoglobulin G (IgG) [26] . Protein concentration of isolated HDL fraction was determined using bovine serum albumin as standard [27] .
Isolation of high-density lipoprotein (HDL)
HDL was isolated from serum samples by sequential ultracentrifugation using Beckman Optima TL Table-Top ultracentrifuge (Beckman Coulter, Brea, CA) and KBr for density adjustment [28] . Serum (0.5 ml) was first adjusted to the density (d) of 1.019 g/ml and the centrifuge tube filled with a d ¼ 1.019 g/ml KBr solution to the total volume of 3 ml. The samples were centrifuged at 5 C for 2 h at 500,000 Â g. After centrifugation remnant particles as well as very low and intermediate density lipoproteins were recovered in the top 1 ml fraction and the bottom was adjusted to a density of 1.063 g/ml using solid KBr, filled to 3 ml with d ¼ 1.063 g/ml KBr solution and centrifuged again (5 C, 3 h, 500,000 Â g). The top 1 ml fraction contained low-density lipoproteins (LDL). To isolate the HDL fraction, the LDL bottom fraction was adjusted with solid KBr to a density of 1.21 g/ml, the vials filled with KBr 1.21 g/ml density solution and then centrifuged (5 C, 18 h, 500,000 Â g). Total HDL was obtained in top 1 ml fraction. The isolated HDL was dialyzed against phosphate-buffered saline (PBS, pH 7.4) and stored at À80 C before analysis.
Measurement of preb-HDL levels
The ability of human plasma samples to generate preb-HDL was analyzed by incubating plasma for 17 h at 37 C in the presence of a Lecithin-Cholesterol Acyltransferase (LCAT) inhibitor (1 mM iodoacetate). The formed preb-HDL particles were quantified by resolving the post-incubation plasma samples with twodimensional crossed immunoelectrophoresis, as previously reported [29] . Briefly, the crossed immunoelectrophoresis consisted of an agarose electrophoresis in the first dimension for separation of lipoproteins with their preb, b and a mobility, followed by electrophoresis in the second dimension using agarose gel containing 7.5% (v/v) rabbit anti-human apoA-I antiserum. For visualization, the gel was dried and stained with Coomassie brilliant blue R250 and the areas under the preb-HDL and a-HDL peaks were calculated. The preb-HDL area was expressed as a percentage of the sum of a-HDL and preb-HDL areas. ApoA-I levels in the preb-HDL and a-HDL fractions were calculated using the total plasma apoA-I concentration.
Measurement of serum CETP, LCAT, PLTP and PON-1 activities
Serum cholesteryl ester transfer protein (CETP) activity was analyzed by a radiometric method as a transfer/exchange of radiolabeled [
14 C]cholesteryl oleate (Amersham Biosciences, Amersham, UK) between exogenously added human low-densitylipoprotein (LDL) and HDL, as reported [30] . Radioactivity in HDL as a measure of transfer activity was determined by liquid scintillation counting. The activity of CETP was expressed as nmol/ml/h. The intra-and inter-assay CVs for CETP were 16 and 12%. Phospholipid transfer protein (PLTP) activity (mmol/ml/h) was determined with a radiometric method as described [31] . The intra-and inter-assay CVs for PLTP were 9 and 12%. Lecithin-cholesterol acyltransferase (LCAT) activity was measured as described [32] . The interassay CV for LCAT was 4%. Paraoxonase-1 (PON-1) activity was measured with a chromogenic method [33] . The intra-assay and inter-assay CVs for PON-1 measurements were 10 and 7%, respectively.
Cell culture
Fibroblasts were obtained from participants by explant culture from a 3 mm punch at a 1 mm skin thickness. Primary cultures were grown in Dulbecco's Modified Eagle MEM (DMEM, Gibco/Thermo Fisher Scientific, Waltham, MA) supplemented with streptomycin (100 mg/ml) and penicillin (100 U/ml) and 20% fetal calf serum (FCS) and maintained at 37 o C and 5% CO 2 in stock flasks. Cells were used till passage 15. Mouse Raw264.7 macrophages were cultured in DMEM (Sigma-Aldrich, St. Louis, MO), 10 mM HEPES, pH 7.4, 10% FCS (Gibco), 100 U/ml penicillin, and 100 mg/ml streptomycin, and the human HuH7 hepatoma cell line in Eagle's minimal essential medium with Earle's salts (EMEM, Sigma-Aldrich) with the above supplements.
Cholesterol efflux from fibroblasts
For the efflux experiments fibroblasts cells were cultured in 24-wells until confluency [34] . Cells were loaded with cholesterol including 0.5 mCi/ml [29] . After washes, cholesterol efflux was carried out for 16 h to serum-free medium containing either 1% serum or 25 mg/ml (as total protein) purified HDL from the subjects under investigation. The radioactivity in the efflux media and in the cells was thereafter determined by liquid scintillation counting, and efflux % calculated.
cDNA constructs
The p.C39X mutation was introduced into OSBPL1A cDNA (AF323726) in pEGFP-C1 (Clontech/TaKaRa Bio, Mountain View, CA) with the QuikChange kit (Agilent, Santa Clara, CA). The wild-type and p.C39X mutant constructs, as well as the plain pEGFP-C1 vector, were used for transfection experiments. For recombinant protein production OSBPL1A cDNA fragments encoding aa 1e208 and 1e38 were generated by PCR and cloned into pGEX1lT (GE Healthcare, Little Chalfont, UK).
Fluorescence microscopy
HuH7 hepatoma cells were transfected with pEGFP-C1-OSB-PL1A-wt or -39X expression constructs using Lipofectamine 2000 (Invitrogen/Life Technologies, Carlsbad, CA). After 24 h, Alexa568-dextran (100 mg/ml; Molecular Probes/Life Technologies, Eugene, OR) was added for 90 min in growth medium to label endocytic compartments. Alternatively, 20 mg/ml of lipid-free human apoA-I (kindly donated by Dr. Peter Lerch, the Swiss Red Cross) labeled with Alexa Fluor 568 protein labeling kit (Thermo Fisher, Waltham, MA) was added in serum-free DMEM, 1 mg/ml fatty acid-free BSA, and incubated for 90 min at 37 C. The cells were fixed and mounted for fluorescence microscopy. In some cases LE/lysosomes were stained with anti-Lamp1 H4A3 (Santa Cruz Biotechnology, Dallas, TX). The specimens were imaged using a Leica (Wetzlar, Germany) SP8 TCS confocal microscope and a 63Â HC PL APO CS2 water immersion objective. Image stacks were deconvoluted using WPL-method (Wiener Filter Preconditioned Landweber) in Parallel Iterative Deconvolution plugin for Fiji.
For co-localization analysis, the image stacks were transformed into sum projection images and non-specific background was removed. Mander's co-localization coefficient was quantified from manually segmented cells using FiJi. Student's t-test was used to assess statistical difference of means.
Co-immunoprecipitation of OSBPL1A with Rab7
To assess the interaction of OSBPL1A-39X with Rab7, HuH7 cells were cotransfected with OSBPL1A-wt or -39X in pEGFP-C1 (Clontech/TaKaRa Bio, Mountain View, CA) or the empty vector, and Xpress TM -Rab7 cDNA in pcDNAHisMaxC. After washes, the cells were lysed in 10 mM Hepes, pH 7.4, 150 mM NaCl, 0.5 mM MgCl 2 , 10% glycerol, 1 mM DTT, 0.5% Triton X-100, EDTA-free protease inhibitor cocktail (Roche Diagnostics, Basel, Switzerland) and centrifuged to remove cell debris. Cleared lysates were incubated overnight at þ4 C with anti-Xpress™ monoclonal antibody (Invitrogen/Life Technologies) and immune complexes were pulled down with protein G Sepharose 4 Fast Flow (GE Healthcare). Precipitates were analyzed by SDS-PAGE and Western blotting using antibodies against the Xpress™ epitope and anti-GFP (A6455, Life Technologies).
Pull-down with glutathione-S-transferase fusion proteins
GST fusion proteins were produced in E. coli BL21 (DE3) by employing a standard protocol. HuH7 cells transfected for 24 h with Xpress TM -Rab7 were lysed in 20 mM Hepes, pH 7.4, 100 mM Kacetate, 5 mM MgCl 2 , 1 mM DTT, 0.5% Triton X-100, EDTA-free protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany) and subjected to pull-down with 10 mg GST or GST fusion proteins and Glutathione-Sepharose 4B (GE Healthcare). After washes with the above buffer without Triton X-100 and the protease inhibitors, the beads were boiled with Laemmli sample buffer, separated on 10% SDS-PAGE, and Western blotted with antiXpress™.
Bioinformatics
For analysis of the OSBPL1A p.C39X mutation the European ancestries in the Exome Variant Server database (ESP, http://evs.gs. washington.edu/EVS/) and the Genome of the Netherlands database (Go-NL, http://www.rug.nl/research/genetics/databases/ genomeofthenetherlands/) [35, 36] were used.
Statistical analyses
Because of the small number of individuals included in the study we provide individual data. The non-parametric Kruskal-Wallis test or Student's t-test were performed to test for significant differences. The statistical results were calculated with SPSS vs22 software (IBM, Armonk, NY).
Results
Gene and protein analysis of OSBPL1A p.C39X variant
The heterozygous genetic variant p.C39X (c.112-115dup) in OSBPL1A gene was identified in a recent population screen to detect the underlying genetic abnormality in patients with extremely low plasma HDL-C levels below the 1st percentile [14] (Fig. 1A) . The 4-nucleotide duplication causes a frameshift that replaces cysteine 39 with a stop codon. The allele thus encodes a short, truncated a Individual II-2 ( Fig. 1A) was not willing to participate in the study. amino-terminal protein fragment. The p.C39X variant was found with a frequency of 0.38% in European ancestries in the Exome Variant Server database (ESP), however, no mutation carriers were found in The Genome of the Netherlands database (Go-NL) [35, 36] . The mutation was not found in 40 patients with elevated plasma HDL-C levels above the 95th percentile. The site of the mutation in OSBPL1A protein is depicted in Fig. 1B . Western blot analysis of fibroblasts derived from a p.C39X carrier revealed a reduced cellular level of full-length OSBPL1A protein (Fig. 1C) , consistent with the notion that the variant allele carriers have a reduced dose of functional OSBPL1A protein in their isolated fibroblasts. In contrast to the response in ATP-binding cassette transporter A-1 (ABCA1) western blotted for a comparison, the cellular level of OSBPL1A protein could not be induced with the liver X receptor (LXR) agonist T0901317 in either non-carriers or carriers of the mutation, suggesting that OSBPL1A is not a target of LXRs.
Biochemical analysis of plasma
Two carriers and two non-carriers of the OSBPL1A mutation were identified in the family, and the mutation co-segregated with the low HDL-C phenotype (Fig. 1A) . The plasma HDL-C and apoA-I concentrations in the mutation carriers were markedly lower as compared to non-carriers (Fig. 1A, Table 1 ). None of the other lipid parameters nor lipid transfer proteins, LCAT or paraoxonase-1 (PON-1) activities were different among carriers and non-carriers of the OSBPL1A variant ( Table 1) . Analysis of the HDL composition and pre-b-HDL level and its formation capacity revealed no significant differences between the carriers and non-carriers (Table 2 ).
The OSBPL1A p.C39X variant and cholesterol efflux
We tested the capacity of the serum and HDL derived from the two heterozygous OSBPL1A p.C39X mutation carriers and two noncarrier relatives to act as acceptors in a macrophage cholesterol efflux assay, the first step in the reverse cholesterol transport process. We found that cholesterol efflux capacity from [ 3 H] cholesterol-acLDL-loaded Raw264.7 macrophages to serum from the carriers was significantly (p < 0.01) reduced as compared to non-carriers (Fig. 2) . When cholesterol efflux to purified HDL of the carriers at an equal protein concentration (25 mg/ml) was assessed, no consistent difference was observed. efflux is expressed as % radioactivity in the medium of the total counts in medium and cells. The data is presented as a scatter plot in which the symbols represent the % efflux values for 5e6 macrophage cultures/individual. Data are presented as mean ± SD. When data for the two mutation carriers and the two non-carriers are pooled, cholesterol efflux to serum is significantly lower among the mutation carriers compared to the non-carriers (p < 0.01; Student's t-test). There is no significant difference between the genotypes in efflux capacity to isolated HDL. Fig. 3 . Cholesterol efflux capacity of fibroblasts from p.C39X non-carriers and a carrier. Cholesterol efflux capacity from fibroblasts isolated from skin biopsy specimens of two OSBPL1A mutation non-carriers (Control) and a carrier (C39X) was measured using human apoA-I (A) and total HDL (B) as acceptors. The cells were labeled for 24 h with [
cholesterol in the absence or presence of the LXR agonist T0901317 (3 mM; indicated at the bottom as þLXR or ÀLXR). Efflux to human apoA-I (10 mg/ml) or HDL (20 mg/ml) was measured during a 4-h time span. The efflux% indicates the counts in the medium divided by the total counts in medium and cells; Experiments were repeated on 2e3 different days, in triplicate on each day (each symbol represents an individual measurement). Statistical significance was tested using Student's t-test; ***p < 0.001 versus each control.
To study the effect of the OSBPL1A mutation on cellular cholesterol efflux capacity, fibroblasts derived from a p.C39X carrier and two non-carrier controls were tested. [ 3 H]cholesterol efflux to human HDL or lipid-free apoA-I was measured in the absence or presence of an LXR agonist. The fibroblasts derived from the p.C39X carrier showed under both conditions significantly reduced cholesterol efflux to purified lipid-free apoA-I ( Fig. 3A ; p < 0.001) but not to mature HDL particles (Fig. 3B) , as compared to the controls.
The OSBPL1A p.C39X variant encodes a soluble protein fragment
GFP fusions of OSBPL1A-wt and the -39X variant were overexpressed in HuH7 cells to monitor their subcellular targeting. In accordance with Johansson et al. [19] , wild-type (wt) GFP-OSBPL1A localized on clustered or fused large perinuclear late endosomal (LE) organelles, many of which co-localized with the late endosome/lysosome marker Lamp1 (data not shown) and with the internalized fluid-phase endocytic marker Alexa568-dextran (Fig. 4A) . Moreover, the protein co-localized in some endosomes with Alexa568-labeled apoA-I internalized into the cells (Fig 4E) . The apoA-I-containing organelles were occasionally encircled by the OSBPL1A signal, demonstrating that they represent apoA-I internalized in endosomes decorated by OSBPL1A or by ER cisternae with associated OSBPL1A [37] . OSBPL1A-39X, the short truncated N-terminal fragment, was only present in the cytosolic compartment and in the nucleus (Fig. 4B,F) , and was practically indistinguishable from the GFP control (Fig. 4C,G) . Quantification of the fluorescence signals and their overlap revealed a significant colocalization of GFP-OSBPL1A-wt, but not the C39X fragment, with both internalized markers (Fig. 4D,H) .
OSBPL1A is known to be recruited onto LE/lysosomes by the small GTPase Rab7, which interacts with the N-terminal region of OSBPL1A containing three ankyrin repeats [19, 20] . We therefore employed a co-immunoprecipitation approach to study whether the N-terminal OSBPL1A-39X might have the capacity to interact with Rab7. Cells were transfected with GFP, GFP-OSBPL1A-wt or GFP-OSBPL1A-p.39X, together with Xpress TM -Rab7, followed by immunoprecipitation with anti-Xpress™ and Western blot analysis of the precipitates. While OSBPL1A-wt precipitated abundantly with Rab7, none of the OSBPL1A-39X fusion protein was found in the precipitate (Fig. 5) , strongly suggesting that the 39X fragment fails to bind Rab7. This result was confirmed by a pull-down assay employing lysates of cells transfected with Xpress TM -Rab7 and a purified GST-39X fusion protein: While the positive control, OSB-PL1A N-terminal fragment (aa 1e208), pulled-down Rab7, the GST-39X failed to do so (Fig. 5B ).
Discussion
In a previous study we identified a variant in the OSBPL1A gene, p.C39X, in subjects with very low (<1st percentile) plasma HDL-C levels [14] . The p.C39X variant results in a truncated protein consisting of only 38 N-terminal amino acid residues of OSBPL1A. We now demonstrate that this variant represents a loss-of-function leading to a reduced dose of functional OSBPL1A protein in fibroblasts of the carriers.
Plasma HDL-C and apoA-I levels were reduced in heterozygous carriers of the OSBPL1A mutation, and plasma from the carriers showed a decreased cholesterol efflux acceptor capacity from cholesterol-loaded macrophages, consistent with the reduced concentration of HDL-C and apoA-I. Concomitantly, isolated HDL from the mutation carriers, when employed at equal protein concentration as acceptor, displayed no defect in cholesterol efflux, suggesting that the properties of endogenous HDL in this functional assay are not severely affected. Moreover, fibroblasts from an OSBPL1A p.C39X mutation carrier were defective in cholesterol efflux to lipid-free apoA-I but not to mature HDL particles, indicating a specific defect in ABCA1-mediated efflux.
OSBPL1A has previously been connected with the cellular cholesterol homeostasis as illustrated in conditions of overexpression as well as knock-down of the protein. Defective cholesterol efflux from cholesterol-loaded macrophages to HDL particles was observed in transgenic mice overexpressing human OSBPL1A under scavenger receptor A promoter [24] . On the other hand, Vihervaara et al. [22] observed that knock-down of Osbpl1A with RNAi in Raw264.7 macrophages resulted in defective cholesterol efflux capacity to apoA-I, which is similar to the phenotype observed in our OSBPL1A mutant. The function of OSBPL1A has thus far not been studied in tissues responsible for bulk HDL biogenesis, the liver and the intestine [38] . However, the reported functional links with cholesterol efflux to apoA-I or HDL indicate that OSB-PL1A, which is expressed in both liver [39] and intestine (http:// biogps.org/), is likely to contribute to the biogenesis and/or secretion of HDL particles [40] . In the present experiments we showed that fluorescent apoA-I added in the medium of cultured hepatocytes transfected with OSBPL1A partially co-localized with the OSBPL1A in endosomal compartments. This observation is consistent with the notion that OSBPL1A may regulate the intracellular trafficking and handling of apoA-I.
The short amino-terminal OSBPL1A-39X fragment was localized in the cytosolic compartment, while the wild-type OSBPL1A localizes to late endocytic compartments via an interaction with the small GTPase Rab7 [19, 20] and regulates late endosome/lysosome motility, tethering and fusion [20, 22, 23] . The present data demonstrate that the OSBPL1A-39X fragment is unable to interact with Rab7, consistent with the lack of LE/lysosomal localization. This fragment also lacks the region between the pleckstrin homology domain and the ORD that mediates the homodimerization of OSBP [41, 42] , heterodimerization of OSBP with OSBP2/ORP4L [42] , and ORP9 with ORP11 [43] . This strongly suggests that the 39X fragment is unable to dimerize with full-length OSBPL1A encoded by the other, intact allele in the heterozygous variant carriers, and to perturb its function in a dominant fashion. The above observations provide evidence that the OSBPL1A-39X protein fragment represents a loss-of-function. Whether this loss-of-function affects the secretion of apoA-I from the liver or intestine remains to be investigated.
Until now, we have only identified one nuclear family with a nonsense mutation in OSBPL1A. Sequencing of more subjects with the low HDL-C phenotype will hopefully lead to the identification of additional OSBPL1A mutation carriers to allow replication of the present findings and survey of more detailed mechanisms behind the low HDL-C. Further study is required to unequivocally establish whether the OSBPL1A p.C39X mutation has a causal relationship with the low-HDL phenotype; At present we cannot exclude the possibility that unknown linked mutation(s) may have an impact on the observed low-HDL phenotype.
To conclude, our data suggest that the p.C39X loss-of-function mutation identified in OSBPL1A affects cholesterol removal from cells and associates with the low plasma HDL cholesterol levels. The present work represents the first report on a human OSBPL1A mutation and raises the possibility that rare mutations in OSBPL genes may contribute to dyslipidemias.
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